Scientists test 'Living Drug' to fight advanced skin cancer
NCT ID NCT05176470
Summary
This early-stage study is testing a two-part treatment for advanced melanoma that has spread. Doctors take a patient's own immune cells from a tumor, grow them in a lab, and then infuse them back, combined with an immunotherapy drug (pembrolizumab). The goal is to see if this approach is safe and can shrink tumors before surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.